Successful chemotherapy with liposomal doxorubicin for metastatic Kaposi's sarcoma without skin involvement in the kidney transplant recipient

Saudi J Kidney Dis Transpl. 2021 Mar-Apr;32(2):548-553. doi: 10.4103/1319-2442.335469.

Abstract

Kaposi's sarcoma (KS), one of the most typical malignancies after kidney transplantation, is strongly associated with human herpes virus 8 infection. More than 90% of patients had primary skin changes, which make the diagnosis easier and faster. The lack of skin lesions is considered rare, especially in the iatrogenic type of sarcoma, including patients on immunosuppression and may cause a diagnostic challenge due to the variety of organ involvement, imitating other diseases. The aim of this case presentation is to raise attention to the atypical clinical manifestation of this malignancy. Currently, several different therapeutic options are available for patients with KS, including reduction of immunosuppression, conversion of immunosuppression to mTOR inhibitors, or chemotherapy. Here, we present an unusual case of advanced KS human immunodeficiency virus-negative patient after kidney transplantation without primary skin involvement.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antibiotics, Antineoplastic / therapeutic use*
  • Doxorubicin / analogs & derivatives*
  • Doxorubicin / therapeutic use
  • Female
  • Humans
  • Immunocompromised Host
  • Kidney Transplantation / adverse effects
  • MTOR Inhibitors
  • Polyethylene Glycols / therapeutic use
  • Sarcoma, Kaposi / diagnosis
  • Sarcoma, Kaposi / drug therapy*
  • Transplant Recipients

Substances

  • Antibiotics, Antineoplastic
  • MTOR Inhibitors
  • liposomal doxorubicin
  • Polyethylene Glycols
  • Doxorubicin